SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions of a potential short squeeze, fueled by its high short float and days to cover. Recent news about the company's launch of menopause and perimenopause treatments is driving bullish sentiment. The community is actively watching for a breakout above key resistance levels.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast ($MVST) is trending amid optimism in the battery sector and discussion around China's new export curbs on lithium battery components. Community members are highlighting the company's profitability compared to peers and potential catalysts like upcoming earnings and expansion plans. Some traders anticipate a significant short squeeze due to these factors and are watching volume closely.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate the sustainability of its recent surge, with some pointing to potential market manipulation and insider selling. Concerns are rising about a possible offering or short report impacting the stock, contrasting with the continued excitement around quantum computing and the company's long-term potential. The divergence between RGTI and its peers, particularly IONQ, is fueling speculation about the factors driving the stock's price action.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor Manufacturing is trending due to anticipation surrounding its upcoming earnings report and the broader implications for the semiconductor industry, particularly in relation to AI. The community is actively discussing potential revenue and EPS numbers, with some investors buying options in anticipation of a positive earnings surprise. Additionally, there's conversation around the potential for increased AI-related chip demand, and a possible collaboration with Intel.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros ($OMER) is trending amid community excitement around a potential partnership deal and anticipation of regulatory approval for Narsoplimab. Bullish sentiment is fueled by analyst upgrades and speculation of a short squeeze, while some traders discuss technical analysis and potential entry points. Community members express optimism about the company's prospects and upcoming milestones.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending with significant volume as chatter swirls around a potential short squeeze and upcoming presentations at the GITEX Global conference in Dubai. Community members are actively discussing the company's AI-driven drug discovery platform and potential partnerships, with some drawing comparisons to past short squeeze events. Some are speculating about news from Dubai with others suggesting there are big investors buying in.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

Fueled by speculation around Trump's comments on cooking oil supply chains, Sadot Group Inc. is trending with significant after-hours volatility and high relative volume. The community is actively discussing the low float and potential for a short squeeze, with some debating its long-term value amidst the recent public offering. Others point to the company's financials and potential for a bitcoin treasury strategy as reasons for optimism.

ATIF Holdings Ltd. engages in the provision of financial consulting services. It is also involved in merger and acquisition business advisory, post-listing compliance, management support, and related services. The company was founded on January 5, 2015 and is headquartered in Lake Forest, CA.

ATIF Holdings Ltd

ZBAI is trending due to its potential as a low-float runner and recent news about a merger with Mask Global, a company connecting Web2 and Web3. Community members are discussing the possibility of a parabolic breakout and high price targets, citing the stock's thin float and potential for a short squeeze. Some traders are drawing comparisons to other micro-float stocks that have experienced significant gains recently.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

UAL is trending following strong Q2 earnings from competitor DAL, leading to sector-wide gains. Community members are discussing potential upside and call option activity, while analysts are weighing in with price target upgrades. Mixed perspectives exist, with some highlighting UAL's individual merits and upcoming earnings, while others express concern for macro factors.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

BITF is trending as investors discuss its strategic pivot towards high-performance computing (HPC) and AI, potentially decoupling it from Bitcoin's price action. The community highlights upcoming catalysts like the CEO's X space appearance and the company's potential to reach valuations similar to its competitors. There's also discussion around its growing power capacity and possible data center partnerships, fueling speculation about significant future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The U.S. Food and Drug Administration has sent a letter to Novo Nordisk (NVO) CEO Maziar Mike Doustdar regarding the company’s promotional communication featuring Oprah Winfrey, alleging that the video is false or misleading.The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024. It also subsequently appeared on Hulu. The video is a 42-minute special program hosted by Oprah Winfrey, featuring patient testimonials from individuals who struggle with obesity and excessive weight, including those who have used Novo’s Wegovy, Ozempic, or Victoza.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025">alleged</a> in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. The video was also not submitted at the time of initial dissemination or publication as required by law, the agency said.“These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks,” the agency said.The FDA also noted that obesity and type 2 diabetes are significant public health concerns in the U.S., and consumers who seek medical treatment for these conditions should receive truthful and nonmisleading information regarding the serious risks associated with the use of the drugs. While Novo’s Wegovy is used for weight management, its Ozempic and Victoza are used to treat type 2 diabetes.The FDA said that several advisory comments dated as long back as 2010 addressed draft promotional communications for Victoza with certain similarities to the aforementioned video. The agency expressed concerns that <a href="https://stocktwits.com/symbol/NVO">Novo</a> is promoting the three drugs in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite the FDA’s prior comments.While the video includes numerous representations of the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, it omits important risk information or minimizes the risks associated with these drug products, the FDA said. Only four minutes in total were devoted to the important risks associated with GLP-1 drugs, such as Wegovy, the FDA said.The video also omits reference to how the drugs are contraindicated in patients with a personal or family history of Medullary Thyroid Cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2, it added. The omissions are exacerbated by statements from Amanda Velazquez, a paid consultant of Novo, made on the video, the FDA said.NVO stock is down by 33% this year and by 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">Hims &amp; Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ 

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 

Equity

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 


Novo Nordisk (NVO) announced on Tuesday that its new obesity treatment, Cagrilintide, reduced body weight by 11.8% after 68 weeks in a late-stage study.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916427">reported</a> an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in the trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy, plus lifestyle intervention, for adults with obesity or overweight and a weight-related comorbidity without diabetes. The above levels of weight reduction were observed in participants who adhered to the treatment. Regardless of adherence, average weight loss with Cagrilintide was 11.5% compared to 3.0% with placebo after 68 weeks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_9_59_21_AM_png_2efadb4b5b.webp" alt="NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment that the stock rallied only 2-3% on good news.<stembedurl>https://stocktwits.com/King990/message/628811943</stembedurl>Cagrilintide works differently from currently approved GLP-1-based treatments for weight loss, including Novo’s Wegovy and Eli Lilly’s Zepbound. The new drug mimics the naturally occurring hormone amylin that helps control blood glucose levels and appetite by slowing gastric emptying, reducing glucagon secretion, and promoting satiety.The company also stated that approximately one in three participants receiving Cagrilintide achieved 15% or more weight loss, compared to approximately one in 20 participants receiving a placebo, when patients adhered to the treatment.Novo stated that the drug was well-tolerated, while adding that the most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. These side effects were mainly temporary and mild to moderate, and 1% of participants discontinued the study due to nausea, compared to 0.1% of participants who received a placebo.“We’re excited that these data, the first phase 3 data of a next-generation amylin therapy, show promise, and we look forward to further investigating cagrilintide’s potential in the dedicated phase 3 RENEW programme,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk.Another late-stage programme investigating the efficacy and safety of Cagrilintide in people with obesity or overweight is due to start in the fourth quarter of this year.Separately, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://bloomberg.com/news/articles/2025-09-16/novo-plans-to-seek-us-approval-for-its-high-dose-obesity-shot?sref&amp;#61;8QBk7toa">reported</a> on Tuesday that Novo plans to seek U.S. regulatory approval for a high-dose version of Wegovy. Though the drugmaker hasn’t yet formally announced its U.S. plans, it intends to file for the U.S. Food and Drug Administration approval, said Lange at the European Association for the Study of Diabetes conference in Vienna, according to the report.NVO stock is down 34% this year and by about 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-probe-into-174000-plus-tesla-model-y-vehicles/chwyiNgRdz5">US Regulator Opens Probe Into 174,000-Plus Tesla Model Y Vehicles – Check Out Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-Stage Study

The company reported an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in a trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy. 

Danish drugmaker Novo Nordisk (NVO) has entered into a multi-year research collaboration with Replicate BioScience to develop new therapeutic candidates, the privately held clinical stage company stated on Thursday.The collaboration will bring together Novo’s therapeutic knowledge and drug development expertise with Replicate’s novel srRNA platform to develop new therapeutic candidates to treat obesity, type 2 diabetes, and other cardiometabolic diseases, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://replicatebioscience.com/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes/">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> trended within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. According to Stocktwits data, retail chatter about the stock increased by about 157% over the past 30 days. Shares of the company traded 1% lower at the time of writing.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_10_55_20_AM_png_5dd1ac88ba.webp" alt="NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they have purchased more shares of the company.<stembedurl>https://stocktwits.com/bginvest/message/626846711</stembedurl>Under the new deal, Novo Nordisk will receive a defined, exclusive, and worldwide license to use Replicate’s self-replicating RNA platform for the development and commercialization of treatments. Meanwhile, Replicate will receive research funding and is eligible to receive up to $550 million from Novo, including an up-front cash payment and potential milestone payments. Replicate is also eligible to receive tiered royalties on future product sales as part of the deal.Last month, Novo, which is battling competition from its U.S. rival Eli Lilly, lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.Last week, it was reported that the drugmaker has implemented a hiring freeze, which will apply across all markets and departments, with an exemption for business-critical roles. Former CEO of Novo Nordisk, Lars Fruergaard Jørgensen, had earlier stated that the company is taking measures to sharpen its commercial execution and ensure efficiencies in cost base while continuing to invest in future growth.NVO stock is down 35% this year and approximately 59% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/teva-pharma-announces-fda-approval-for-generic-weight-loss-medication/chs6ffWRdmt">This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today?

Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop and commercialize treatments.

Danish drugmaker Novo Nordisk (NVO) has implemented a hiring freeze, which will apply across all markets and departments, Bloomberg reported on Wednesday, citing a company spokesperson.Business-critical roles, however, would be exempted from the hiring freeze, the report <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-20/novo-nordisk-s-new-ceo-starts-hiring-freeze-in-cost-cutting-push-mejscm29">said</a>. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:564/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_7_07_43_AM_png_be5874fe43.webp" alt="NVO's Sentiment Meter and Message Volume as of 7:08 a.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="564" height="62"><figcaption>NVO's Sentiment Meter and Message Volume as of 7:08 a.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to trade over $100 in a year.<stembedurl>https://stocktwits.com/Eesnimi/message/625897097</stembedurl>Another user opined that the stock can rally up to $70 if it can break the $55 mark.<stembedurl>https://stocktwits.com/trading_momentum/message/625893966</stembedurl>Former CEO, Lars Fruergaard Jørgensen, said earlier this month that the company is taking measures to sharpen its commercial execution further, and ensure efficiencies in cost base while continuing to invest in future growth. Novo’s new CEO, Maziar Mike Doustdar, took charge on August 7.Last month, the company, battling competition from its U.S. rival Eli Lilly, <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-slashes-full-year-guidance/cho9UwAR5yE">lowered</a> its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.The company now sees lower growth for Wegovy in the U.S. obesity market and for Ozempic in the U.S. diabetes market, as well as lower-than-expected penetration for Wegovy in select international operations markets.Novo’s <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/careers/find-a-job/career-search-results.html?searchText=&amp;countries=&amp;categories=">website</a> currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark. According to the company, it employs over 77,000 people in 80 offices around the world.NVO stock is down by 36% this year and by about 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ioc-bpcl-reportedly-resume-russian-crude-purchase-as-discounts-widen/chsiZrQRdh3">IOC, BPCL Reportedly Resume Russian Crude Purchase As Discounts Widen</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year

Novo’s website currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark.

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the risk of kidney function decline, end-stage kidney disease, and cardiovascular death in patients with type 2 diabetes and chronic kidney disease (CKD).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO</a> trended within the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels. According to data from Stocktwits, retail chatter around the stock jumped 67% over the past 24 hours and by about 197% over the past seven days as of early hours on Tuesday. &nbsp;<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_1_02_48_PM_png_e2a2c52a54.webp" alt="NVO's Sentiment Meter and Message Volume as of 1:03 p.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>NVO's Sentiment Meter and Message Volume as of 1:03 p.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user said that they do not see much downside for the stock.<stembedurl>https://stocktwits.com/bullish51892/message/625797538</stembedurl>The approval from Health Canada for the indications is based on the results of a trial in which Semaglutide 1 mg demonstrated a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo. Semaglutide is the active ingredient in Ozempic.The trial was initiated in 2019 and was stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/ozempic-ckd-indication-press-release-english-aug192025.pdf">said</a>.Ozempic is already indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control. It was approved by Health Canada in 2018.CKD and type 2 diabetes are interconnected. Around 40% people with type 2 diabetes develop the disease. CKD is defined as the presence of kidney damage, or a decreased level of kidney function, for a period of three months or more. It is estimated to impact nearly four million Canadians.Novo is currently attempting to increase the use cases for its GLP-1 category drugs, including Ozempic and the weight-loss drug Wegovy. Last week, the company said that the U.S. Food and Drug Administration has also approved Wegovy for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. MASH is a serious liver disease characterized by fat accumulation, inflammation, and liver cell damage.NVO stock is down by 37% this year and by about 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ptc-therapeutics-stock-in-limelight-after-fda-refuses-approval-for-drug-to-treat-neurodegenerative-disease/chsgFLxRdW5">PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health Canada Approves Novo’s Ozempic to Reduce Risk Of Kidney Function Decline, Cardiovascular Death

The approval from Health Canada for the indications is based on the results of a trial in which Semaglutide 1 mg demonstrated a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo. 

Health Canada Approves Novo’s Ozempic To Reduce Risk Of Kidney Function Decline, Cardiovascular Death

NuShares ETF Trust - Nuveen Dividend Growth ETF

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$28.84
Prev Close	$28.73
Open	$28.83
Dividend Yield	N/A
50-Day Moving Average	$29.04
Beta	N/A
Avg. Volume	121.65
PE Ratio	N/A

52-Week High	$29.64
52-Week Low	$24.33
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

NDVG
NuShares ETF Trust - Nuveen Dividend Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest NDVG News

NDVGNuShares ETF Trust - Nuveen Dividend Growth ETF